Meet Subclade K: The New Flu Variant Shaping the 2025 Winter

1. Introduction

The cyclical nature of seasonal influenza is driven by the relentless evolution of the virus, a phenomenon primarily characterized by antigenic drift. As global health systems prepare for the 2025-2026 Northern Hemisphere winter, surveillance networks have identified a significant perturbation in the viral landscape: the rapid emergence and dominant establishment of a novel Influenza A(H3N2) lineage. Scientifically classified as subclade J.2.4.1 and widely referred to in media and public health communications as the "K variant" or "Subclade K," this viral strain represents a distinct evolutionary branch that has diverged antigenically from the strains selected for the season's vaccine formulations.¹

The influenza A(H3N2) subtype is historically associated with the most severe seasonal epidemics, disproportionately affecting the elderly and those with compromised immune systems. Consequently, the emergence of a drift variant within this subtype is a matter of urgent public health concern. The K variant's trajectory—first detected in the waning weeks of the Southern Hemisphere season and subsequently exploding in prevalence across the United Kingdom and Europe in late 2025—suggests a virus with enhanced transmissibility or immune escape properties.³

This report provides an exhaustive analysis of the K variant. It integrates genomic surveillance data, structural biology, clinical reports, and vaccine effectiveness studies to construct a holistic picture of the threat. We explore the specific amino acid substitutions that define the clade, the epidemiological dynamics observed in sentinel countries like the UK, the mechanistic basis for the observed vaccine mismatch, and the complex immunological phenomena—specifically Original Antigenic Sin—that are driving age-stratified patterns of infection and protection.⁵

1.1 The Context of the 2025-2026 Season

The 2025-2026 influenza season arrives at a complex intersection of post-pandemic immunological adjustments and viral competition. Following several years of disrupted transmission patterns due to COVID-19 interventions, seasonal influenza has sought a new equilibrium. The K variant's emergence is notable not just for its genetic novelty but for its timing. By appearing late in the Southern Hemisphere season, it effectively bypassed the surveillance window used to select strains for the Northern Hemisphere vaccine, creating a classic "mismatch" scenario.³

Health authorities, including the Centers for Disease Control and Prevention (CDC) and the European Centre for Disease Prevention and Control (ECDC), have flagged this variant as a "variant of concern" for the current season.⁷ The preliminary data indicates that while the variant does not appear to possess intrinsic hyper-virulence, its ability to evade neutralizing antibodies—particularly in adults with complex immune histories—poses a risk of high case volumes and subsequent pressure on healthcare infrastructure.⁸

2. Molecular Virology and Evolutionary Biology

To understand the implications of the K variant, one must first deconstruct its molecular architecture. Influenza A viruses are categorized by their surface proteins: hemagglutinin (HA) and neuraminidase (NA). The HA protein is the primary target for neutralizing antibodies and is the component of the virus that undergoes the most rapid evolutionary change.

2.1 Phylogenetic Lineage and Classification

The K variant belongs to the 2a.3a.1 clade of Influenza A(H3N2). The nomenclature "K" is a shorthand for the subclade J.2.4.1, which itself evolved from the J.2.4 lineage. This lineage is distinct from the J.2 subclade that predominates in the vaccine reference strains.²

Phylogenetic analysis reveals that the J.2.4.1 subclade diverged significantly during the mid-2025 period. While the J.2 parent lineage was circulating globally and was chosen for the vaccine, the J.2.4.1 branch acquired a constellation of mutations that conferred a fitness advantage, likely driven by immune pressure in populations with high levels of prior immunity to J.2-like viruses.¹⁰

2.2 The Mutation Constellation: Structural Implications

The defining characteristic of Subclade K is a specific set of amino acid substitutions in the HA1 subunit of the hemagglutinin protein. Sequence analysis from GISAID and national laboratories identifies seven critical mutations relative to the A/Croatia/10136RV/2023 vaccine strain. These mutations are not randomly distributed; they cluster in key antigenic sites (A, B, and D) that are critical for antibody binding.⁴

Table 1: Detailed Molecular Characterization of H3N2 Subclade K (J.2.4.1) Mutations

Residue Position (HA1)	Mutation (Wildtype → Variant)	Antigenic Site	Structural and Functional Impact
135	T135K (Thr to Lys)	Site A	Glycosylation Loss. Threonine (T) is essential for the N-X-S/T glycosylation motif. Its replacement with Lysine (K) removes an oligosaccharide chain. This unmasks the underlying epitope, changing the surface topology and charge distribution.4
144	S144N (Ser to Asn)	Site A	Glycosylation Gain (+CHO). This mutation introduces a new Asparagine residue, creating a potential N-linked glycosylation site (N-X-S/T). The addition of a bulky glycan here acts as a "shield," physically blocking antibodies from binding to Site A.4
158	N158D (Asn to Asp)	Site B	Critical Glycosylation Loss. Site 158 is located at the very tip of the HA head, adjacent to the receptor-binding site. The loss of this glycan is a major antigenic determinant. It exposes the receptor-binding region to the immune system, but in a conformation that likely differs from historical strains.4
160	I160K (Ile to Lys)	Site B	Frequently associated with the modulation of the 158 glycosylation site. The shift to a positively charged Lysine residue alters the electrostatic potential of the HA head, affecting antibody affinity.4
173	Q173R (Gln to Arg)	Site D	Substitutes a neutral residue for a positively charged Arginine. Site D is a lateral face of the HA head; mutations here often contribute to "drift" by escaping antibodies that bind to the side of the trimer.4
189	K189R (Lys to Arg)	Site B	A conservative substitution (both are basic), but located in a critical antigenic loop. This mutation is a marker of the J.2.4 parent lineage.10
328	T328A (Thr to Ala)	Stalk	Located in the HA2 subunit or the stalk region. Stalk mutations can influence the pH stability of the virus, potentially affecting fusion kinetics and environmental stability.4

2.3 The "Glycan Shield" Dynamics

A central theme in the evolution of Subclade K is the remodeling of the glycan shield. Influenza viruses use host-derived sugars (glycans) to coat their surface proteins, effectively hiding vulnerable epitopes from the immune system. However, a shield that is too dense can hinder the virus's ability to bind to host cell receptors.

The K variant exhibits a complex "trade-off" strategy:

1. Loss at 135 and 158: The virus has stripped away glycans at these positions. In theory, this makes the virus more exposed. However, if the circulating antibodies in the human population are targeting the glycan itself or the specific shape of the glycosylated protein, the removal of the glycan renders those antibodies useless. This is a mechanism of immune escape via epitope unmasking—presenting a "naked" surface that the adult immune system does not recognize because it is imprinted on a "clothed" (glycosylated) version.¹⁰

2. Gain at 144: Simultaneously, the virus appears to be adding a glycan at position 144. This effectively moves the shield to a new location, blocking a different set of antibodies.

This dynamic remodeling creates a virus that is distinctively different in 3D space compared to the J.2 vaccine strain, which retains the older glycosylation pattern. This structural divergence provides the mechanistic basis for the extensive spread observed in early surveillance data.¹³

3. Global Epidemiological Surveillance

The epidemiological footprint of Subclade K has expanded rapidly since its initial detection. The trajectory of the virus highlights the interconnected nature of global transmission and the speed with which a fit variant can achieve dominance.

3.1 Origin and Southern Hemisphere Precursors

The origins of Subclade K can be traced to the Southern Hemisphere's 2025 influenza season. While the season in countries like Australia and Chile was characterized by a mix of H1N1 and generic H3N2 strains, the specific J.2.4.1 lineage began to coalesce towards the end of the season (August-September 2025).³

Because the variant surged late, it did not drive the bulk of the Southern Hemisphere's caseload, and thus its potential impact was initially underestimated. More importantly, this late emergence meant that it was not available or prominent enough during the February 2025 strain selection meeting for the Northern Hemisphere vaccine, nor was it the dominant signal during the September 2025 meeting for the 2026 Southern Hemisphere vaccine.³ This timing is the primary culprit for the vaccine mismatch.

3.2 The United Kingdom: A Sentinel for the Northern Hemisphere

The United Kingdom has served as the "canary in the coal mine" for the 2025-2026 season. Surveillance data from the UK Health Security Agency (UKHSA) provides the most detailed early-season characterization of the variant's behavior.

• Dominance: By mid-November 2025 (Week 47), Subclade K accounted for 87% of all genetically characterized H3N2 viruses in England. This near-total replacement of other strains indicates a significant competitive advantage.¹¹

• Temporal Shift: The UK season began "unusually early." Influenza activity rose above baseline levels in October, weeks ahead of the typical seasonal curve. This early onset is a classic hallmark of a drift variant entering a population with low specific immunity.⁴

• Demographic Drivers: The primary vector for this early expansion was school-aged children (5-14 years). Test positivity rates in this group skyrocketed, driving community transmission. This aligns with H3N2's historical pattern, where schools act as amplification hubs.⁴

3.3 United States and North America: The Rising Tide

In North America, the situation mirrors the UK but with a temporal lag of approximately 3-4 weeks.

• Prevalence: As of late November 2025, H3N2 comprises approximately 72% of all subtyped Influenza A viruses in the United States. While genomic sequencing takes time to confirm specific subclades, the rapid rise of H3N2 and the detection of K variant markers in sentinel labs strongly suggest that J.2.4.1 is driving this trend.¹⁶

• Activity Levels: Overall national activity remains "low" but is increasing. However, regional heterogeneity is significant:

• Louisiana: Reporting moderate activity, often an early indicator for the South.

• Colorado and Mississippi: Showing distinct upward trends from minimal levels.¹

• Northeast: Increasing detections in urban centers suggest the virus is seeding densely populated areas.¹⁷

• Canadian Data: Health Canada has issued explicit warnings regarding the mismatch, noting a rise in case counts driven by Subclade K and advising that the season could be "harsh" due to reduced vaccine coverage against infection.³

3.4 Europe and Asia

• Europe: The ECDC reports that the variant is present in all reporting countries and accounts for nearly half of all sequences in the EU/EEA region. The spread is uniform, suggesting multiple introduction events and efficient local transmission.⁴

• Asia: Japan has declared an influenza epidemic earlier than usual. Crucially, data from East Asian countries—which are further along in their epidemic curves—suggests that while case numbers are high, the severity (ratio of cases to hospitalizations) has not spiked disproportionately. This provides a crucial piece of evidence: the K variant is highly transmissible but likely not intrinsically more virulent than previous H3N2 strains.⁴

4. The Immunology of Mismatch: Mechanics and Consequences

The central challenge of the 2025-2026 season is the discordance between the vaccine-induced immunity and the circulating virus. This mismatch is not merely a binary "match/no-match" issue; it is a complex interaction involving manufacturing limitations and the immunological history of the host.

4.1 The Vaccine Strain Selection Timeline

Influenza vaccine production is a logistical leviathan requiring months of lead time.

• February 2025: The WHO and FDA selected the Clade J.2 virus as the H3N2 reference strain for the Northern Hemisphere. At this time, J.2 was the dominant global strain, and J.2.4.1 (K) had not yet emerged or was undetectable.³

• Manufacturing: From March to August, manufacturers produced millions of doses targeting J.2.

• Emergence: By the time Subclade K was identified as a threat in late summer 2025, production was complete and distribution had begun.

4.2 Egg-Adaptation: The "Double Mismatch"

A critical, often overlooked factor is the method of vaccine production. The vast majority of the global flu vaccine supply is produced in hen's eggs. H3N2 viruses grow poorly in eggs and often mutate to adapt to the avian host environment.

• The D186A Mutation: The egg-based vaccine strain (A/Croatia/10136RV/2023) acquired a specific mutation—D186A—during the manufacturing process. This mutation is an "egg-adaptation" marker.¹⁰

• The Consequence:

• Wild Virus (K): Has mutations T135K, N158D, S144N.

• Vaccine Target (J.2): Has T135, N158, S144.

• Actual Egg Vaccine: Has T135, N158, S144 AND D186A.Antibodies raised against the egg vaccine are targeting a protein shape influenced by D186A. When these antibodies encounter the wild K variant, they face a surface that differs both by the evolutionary drift (K mutations) and the lack of the egg mutation. This "double distance" significantly erodes neutralization capacity.19

4.3 Antigenic Characterization Results

Laboratory data quantifies this erosion.

• Ferret Antisera: Serum from ferrets infected with the egg-based vaccine strain shows a >32-fold reduction in reactivity against Subclade K viruses. In influenza serology, a reduction of 8-fold is considered significant; 32-fold represents a profound loss of recognition.¹⁴

• Cell-Based Vaccines: Vaccines produced in mammalian cells (e.g., Flucelvax) avoid the egg-adaptation error (D186A). However, they still suffer from the drift mismatch (J.2 vs K). Consequently, while they perform better than egg-based shots (showing an ~8-fold reduction rather than 32-fold), they remain imperfect matches.¹⁴

4.4 Original Antigenic Sin (OAS) and the Age Paradox

Perhaps the most fascinating—and clinically relevant—finding of the early 2025 season is the dramatic stratification of vaccine effectiveness by age. UKHSA data indicates:

• Pediatric VE: 72–75% effectiveness against hospitalization.

• Adult VE: 32–39% effectiveness against hospitalization.⁶

This discrepancy is best explained by the theory of Original Antigenic Sin (OAS), also known as immune imprinting.

• Mechanism: The immune system "imprints" on the first influenza strain encountered in childhood. For today's adults, that initial H3N2 infection likely occurred decades ago (e.g., 1968, 1990s). Those historical strains had specific glycosylation patterns at sites like 158.

• The Trap: When vaccinated with the current strain, adult B-cells are boosted to produce antibodies against conserved epitopes shared between the vaccine and their childhood strain. However, the K variant has mutated exactly these critical sites (e.g., N158D). The adult immune system produces high titers of "wrong" antibodies—antibodies that bind to the vaccine but miss the K variant.

• The Child's Advantage: Young children have little to no immune history. Their B-cells are "naïve." When vaccinated, they generate a de novo response tailored specifically to the vaccine antigen. Even though the vaccine is mismatched to the K variant, the polyclonal response in children is broad enough to provide cross-protection, unencumbered by "useless" memory B-cells from the past.⁵

5. Clinical Impact and Disease Management

While the virology suggests a virus capable of evading immunity, the clinical picture determines the public health burden.

5.1 Symptomatology

There is no evidence to suggest that Subclade K causes a distinct clinical syndrome compared to other H3N2 lineages. The symptoms remain classic:

• Onset: Sudden and acute.

• Systemic: High fever (>38^C), severe myalgia, malaise, chills.

• Respiratory: Non-productive cough, sore throat, rhinitis.¹

5.2 Severity Profile and Hospitalization

H3N2 seasons are historically more severe than H1N1 or Influenza B seasons.

• Elderly Risk: The primary concern is for adults over 65. The combination of immunosenescence and the OAS-driven vaccine failure (35% VE) creates a high-risk environment. While the virus may not be more virulent per infection, the sheer number of infections due to immune escape will likely drive up absolute hospitalization numbers.¹⁶

• Pediatric Risk: H3N2 is also aggressive in children. However, the unexpectedly high vaccine effectiveness in this group (75%) serves as a crucial firewall. If pediatric vaccination rates are high, this will blunt the transmission of the virus to grandparents and vulnerable adults.⁶

• Mortality: As of week 46 in the US, there have been zero reported pediatric deaths. This is a reassuring early signal, though mortality data often lags. It suggests that while the virus infects easily, it is not causing cytokine storms or rapid deterioration in healthy hosts at a rate higher than usual.²⁴

5.3 Diagnostic Considerations

Current diagnostic platforms remain effective.

• PCR/NAAT: The genetic mutations in Subclade K (HA gene) do not affect the primers used in standard diagnostic panels, which typically target the conserved Matrix (M) or Nucleoprotein (NP) genes.

• RIDTs: Rapid antigen tests also detect the variant, though with their known limitations in sensitivity.¹⁵

5.4 Therapeutic Interventions: Antivirals

A vital component of the response strategy is the use of antivirals. Genotypic surveillance has screened Subclade K isolates for resistance markers.

• Neuraminidase Inhibitors (Oseltamivir/Tamiflu): Analysis of the Neuraminidase (NA) gene shows no resistance mutations. The virus remains fully susceptible.²⁶

• Cap-dependent Endonuclease Inhibitors (Baloxavir/Xofluza): Analysis of the Polymerase Acidic (PA) gene also indicates full susceptibility.

• Clinical Recommendation: Given the reduced vaccine protection in adults, clinicians are advised to prescribe antivirals aggressively for high-risk patients presenting with influenza-like illness (ILI), ideally within 48 hours of symptom onset. This "test-to-treat" strategy is the primary mitigation tool for the 2025-2026 season.³

6. Vaccine Technology and Future Outlook

The emergence of Subclade K serves as a case study for the limitations of the current global influenza vaccine architecture and points toward necessary technological shifts.

6.1 The Failure of Egg-Based Manufacturing

The "double mismatch" caused by egg adaptation (D186A) and antigenic drift (J.2 vs K) highlights the obsolescence of egg-based production. This method, while scalable, is biologically rigid. The virus must adapt to the egg, and in doing so, it often drifts away from the human virus it is meant to mimic.¹⁹

6.2 The mRNA Promise

mRNA technology (Pfizer, Moderna) offers a solution to both the timing and fidelity problems.

1. Fidelity: mRNA vaccines encode the exact genetic sequence of the HA protein. The host cells (human muscle cells) produce the protein exactly as the virus would, preserving complex glycosylation patterns and avoiding egg-adaptive mutations.

2. Agility: The production timeline for mRNA is weeks, not months. Had mRNA platforms been the standard, the K variant identified in August could potentially have been incorporated into a late-season booster or even the primary formulation.²⁷

3. Efficacy: Phase 3 trials of mRNA flu vaccines conducted during matched seasons have shown superior efficacy (up to 34.5% higher) against Influenza A compared to standard of care.²⁹

6.3 Universal Vaccine Targets

The continuous drift of H3N2 reinforces the need for universal influenza vaccines that target the conserved "stalk" of the HA protein rather than the hyper-variable "head." The K variant mutations are concentrated in the head (Sites A, B, D). A vaccine targeting the stalk (which remains largely unchanged in Subclade K) would render these drift events irrelevant.⁵

6.4 Seasonal Outlook: What to Expect

Based on the synthesis of UK and US data, the following trajectory is projected for the remainder of the 2025-2026 season:

• Peak Timing: The season will likely peak early—December to early January in the Northern Hemisphere—driven by the rapid transmission of the K variant.

• Burden: High case volumes are expected. Schools and workplaces will see significant absenteeism.

• Healthcare Strain: Hospitals should prepare for a surge in geriatric admissions. While the virus is not "more lethal," the volume of breakthrough infections in the elderly will translate to bed pressure.

• Mitigation: The "tripledemic" context (Flu + COVID + RSV) requires integrated testing. Masking in high-risk settings and improved ventilation remain effective non-pharmaceutical interventions against the K variant.⁴

7. Conclusion

The "K variant" of Influenza A(H3N2) is a reminder of the relentless evolutionary capacity of the influenza virus. By acquiring a specific set of mutations—most notably N158D and T135K—subclade J.2.4.1 has successfully navigated the landscape of human immunity and vaccine selection.

While the "mismatch" is real, it is not absolute. The public health message must be nuanced: vaccination remains a critical tool, offering robust protection for children and preventing the most severe outcomes in adults. However, the reliance on 70-year-old egg-based manufacturing technology has once again left the global population vulnerable to a predictable evolutionary event. The 2025-2026 season serves as a potent validation for the accelerated transition to mRNA and recombinant vaccine platforms, ensuring that in future seasons, our defenses can evolve as rapidly as the virus itself.

Works cited

1. New type of flu emerges: What to know about the new K variant of ..., accessed November 30, 2025, https://thehill.com/homenews/nexstar_media_wire/5622225-new-type-of-flu-emerges-what-to-know-about-the-new-k-variant-of-influenza-a/

2. National flu and COVID-19 surveillance report: 20 November 2025 (week 47) - GOV.UK, accessed November 30, 2025, https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2025-to-2026-season/national-flu-and-covid-19-surveillance-report-20-november-2025-week-47

3. With an absent CDC and mismatched 'subclade K' flu strain, experts face upcoming season with uncertainty | CIDRAP, accessed November 30, 2025, https://www.cidrap.umn.edu/influenza-vaccines/absent-cdc-and-mismatched-subclade-k-flu-strain-experts-face-upcoming-season

4. Assessing the risk of influenza for the EU/EEA in the context of increasing circulation of A(H3N2) subclade K - ECDC, accessed November 30, 2025, https://www.ecdc.europa.eu/sites/default/files/documents/Threat%20Assessment%20Brief%20-%20Assessing%20the%20risk%20of%20increasing%20circulation%20of%20A%28H3N2%29%20subclade%20K.pdf

5. Immune History and Influenza Vaccine Effectiveness - MDPI, accessed November 30, 2025, https://www.mdpi.com/2076-393X/6/2/28

6. Follow Keyword - Read by QxMD, accessed November 30, 2025, https://read.qxmd.com/keyword/250151

7. A New Flu Threat Emerges: The Rapid Rise of H3N2, accessed November 30, 2025, https://www.eper.com/blog/the-alarming-rise-of-the-h3n2-influenza-variant-what-you-need-to-know/

8. New Flu Variant Could Bring Another Severe U.S. Season - Yahoo News Canada, accessed November 30, 2025, https://ca.news.yahoo.com/flu-variant-could-bring-another-205734311.html

9. Threat Assessment Brief: Assessing the risk of influenza for the EU/EEA in the context of increasing circulation of A(H3N2) subclade K - ECDC, accessed November 30, 2025, https://www.ecdc.europa.eu/en/publications-data/threat-assessment-brief-assessing-risk-influenza-november-2025

10. Emergence of seasonal influenza A(H3N2) variants with immune escape potential warrants enhanced molecular and epidemiological su, accessed November 30, 2025, https://utppublishing.com/doi/pdf/10.3138/jammi-2025-0025

11. Why the Flu Season Has Come Early, accessed November 30, 2025, https://thevillagepharmacy.co.uk/f/why-the-flu-season-has-come-early

12. Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination - PMC - NIH, accessed November 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8262463/

13. Emergence of seasonal influenza A(H3N2) variants with immune escape potential warrants enhanced molecular and epidemiological surveillance for the 2025–2026 season | Journal of the Association of Medical Microbiology and Infectious Disease Canada, accessed November 30, 2025, https://utppublishing.com/doi/10.3138/jammi-2025-0025

14. Early influenza virus characterisation and vaccine effectiveness in ..., accessed November 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12639273/

15. CURRENT EPIDEMIOLOGY, POTENTIAL IMPLICATIONS AND USE OF INFLUENZA ANTIVIRALS Early - Community Pharmacy, accessed November 30, 2025, https://www.communitypharmacy.scot.nhs.uk/nhs-grampian/wp-content/uploads/sites/10/CMO-letter-Seasonal-Influenza-2025-26-Current-Epidemiology-Potential-Implications-and-use-of-influenza-antivirals-002.pdf

16. 2025-2026 Flu Season: Reduced Vaccine Match May Lead to Increased Transmission and Severity, Experts Warn, accessed November 30, 2025, https://www.patientcareonline.com/view/2025-2026-flu-season-reduced-vaccine-match-may-lead-to-increased-transmission-and-severity-experts-warn

17. Global Virus Network Experts: New Flu Strain Underscores Urgent Need for Vigilance, Vaccination, and Investment in Virus Science, accessed November 30, 2025, https://gvn.org/global-virus-network-experts-new-flu-strain-underscores-urgent-need-for-vigilance-vaccination-and-investment-in-virus-science/

18. New Flu Strain 2025: Subclade K Variant Puts U.S. on High Alert - Everyday Health, accessed November 30, 2025, https://www.everydayhealth.com/infectious-diseases/surprise-flu-mutation-puts-us-on-high-alert/

19. Study: Mutations during egg step cut last year's flu vaccine effectiveness | CIDRAP, accessed November 30, 2025, https://www.cidrap.umn.edu/influenza-vaccines/study-mutations-during-egg-step-cut-last-years-flu-vaccine-effectiveness

20. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine - ScienceOpen, accessed November 30, 2025, https://www.scienceopen.com/document_file/730930f0-5db3-4079-983c-d8a265a2a5da/PubMedCentral/730930f0-5db3-4079-983c-d8a265a2a5da.pdf

21. Imprinting of Repeated Influenza A/H3 Exposures on Antibody Quantity and Antibody Quality: Implications for Seasonal Vaccine Strain Selection and Vaccine Performance | Clinical Infectious Diseases | Oxford Academic, accessed November 30, 2025, https://academic.oup.com/cid/article/67/10/1523/4972882

22. Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics | PLOS Pathogens, accessed November 30, 2025, https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1008109

23. New flu strain subclade K | Baptist Health | Jacksonville, FL, accessed November 30, 2025, https://www.baptistjax.com/juice/stories/community-health/new-flu-strain-subclade-k

24. Weekly US Influenza Surveillance Report: Key Updates for Week 45, ending November 8, 2025 | FluView | CDC, accessed November 30, 2025, https://www.cdc.gov/fluview/surveillance/2025-week-45.html

25. Weekly US Influenza Surveillance Report: Key Updates for Week 46, ending November 15, 2025 | FluView | CDC, accessed November 30, 2025, https://www.cdc.gov/fluview/surveillance/2025-week-46.html

26. National flu and COVID-19 surveillance report: 27 November 2025 (week 48) - GOV.UK, accessed November 30, 2025, https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2025-to-2026-season/national-flu-and-covid-19-surveillance-report-27-november-2025-week-48

27. Understanding the Implications of Delaying Seasonal Influenza Vaccine Recommendations: An Industry Perspective - PMC - NIH, accessed November 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12474493/

28. Is the Flu Shot Market a Slam Dunk for mRNA Vaccines? Experts Aren't So Sure, accessed November 30, 2025, https://www.msm.edu/RSSFeedArticles/2023/December/mRNA_Vaccines.php

29. EXPERT REACTION: mRNA flu vaccine is up to 34.5% more effective than current flu vaccines - Scimex, accessed November 30, 2025, https://www.scimex.org/newsfeed/expert-reaction-mrna-flu-vaccine-is-up-to-34-5-percent-more-effective-than-current-flu-vaccines

30. 2025-2026 Flu season outlook | Baptist Health | Jacksonville, FL, accessed November 30, 2025, https://www.baptistjax.com/juice/stories/community-health/flu-forecast